LaSalle Street Station

Sunstone Innovation Challenge Startup Winners Announced at CSULB

Retrieved on: 
Monday, April 24, 2023

The Sunstone Innovation Challenge announced this year’s winners after final pitches at California State University, Long Beach on Thursday, April 20.

Key Points: 
  • The Sunstone Innovation Challenge announced this year’s winners after final pitches at California State University, Long Beach on Thursday, April 20.
  • Event sponsor and private capital firm Sunstone Management provided $25,000 of the prize money through its donor-advised fund, Sunstone Community Fund.
  • “Sunstone is proud to partner with CSULB to support young entrepreneurs,” said John Keisler, Sunstone Management CEO.
  • “The Sunstone Innovation Challenge is the culmination of at least one year of commitment to creating a startup,” said Wade Martin, CSULB IIE director.

Immunovia further strengthens IP portfolio for its IMMray™ PanCan-d signature

Retrieved on: 
Monday, March 7, 2022

This means that the Immunovia IMMray PanCan-d test signature will be further covered by the resultant patent once it is issued.

Key Points: 
  • This means that the Immunovia IMMray PanCan-d test signature will be further covered by the resultant patent once it is issued.
  • Immunovia's IMMray PanCan-d is the first ever blood test dedicated to the early detection of pancreatic cancer.
  • Detection of the disease at an early stage, while still resectable, has the potential to increase survival rates for pancreatic cancer patients.
  • The patent further strengthens our extensive IP portfolio consisting of seven patent families covering biomarkers in pancreatic cancer.

Immunovia further strengthens IP portfolio for its IMMray™ PanCan-d signature

Retrieved on: 
Monday, March 7, 2022

This means that the Immunovia IMMray PanCan-d test signature will be further covered by the resultant patent once it is issued.

Key Points: 
  • This means that the Immunovia IMMray PanCan-d test signature will be further covered by the resultant patent once it is issued.
  • Immunovia's IMMray PanCan-d is the first ever blood test dedicated to the early detection of pancreatic cancer.
  • Detection of the disease at an early stage, while still resectable, has the potential to increase survival rates for pancreatic cancer patients.
  • The patent further strengthens our extensive IP portfolio consisting of seven patent families covering biomarkers in pancreatic cancer.

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Retrieved on: 
Tuesday, January 11, 2022

17/364,047 for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.

Key Points: 
  • 17/364,047 for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.
  • The international (PCT) patent application provides Field Trip with deferred patent filing rights in 150+ countries.
  • Field Trip expects the patent for Tryptamine Prodrugs to be issued in February 2022 and it will expire in 2040.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.

Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates

Retrieved on: 
Thursday, August 5, 2021

WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates.
  • The Company currently has 12 participating trial sites, with data anticipated in the fourth quarter of 2021.
  • Research and development expenses were $4.2 million for the second quarter of 2021, compared to $4.5 million for the second quarter of 2020.
  • General and administrative expenses for the second quarter of 2021 were $3.4 million, compared to $3.5 million for the second quarter of 2020.

LaSalle St. Launches Growth Acceleration Platform For Financial Institutions-Based Wealth Management Programs

Retrieved on: 
Wednesday, December 9, 2020

CHICAGO, Dec. 9, 2020 /PRNewswire/ --LaSalle St., a family of wealth management firms encompassing independent broker-dealer and registered investment adviser (RIA) platforms, today announced the rollout of its Growth Acceleration Platform for financial institutions-based wealth management programs.

Key Points: 
  • CHICAGO, Dec. 9, 2020 /PRNewswire/ --LaSalle St., a family of wealth management firms encompassing independent broker-dealer and registered investment adviser (RIA) platforms, today announced the rollout of its Growth Acceleration Platform for financial institutions-based wealth management programs.
  • The new platform is another example of LaSalle St.'s commitment to providing the institutions and financial professionals it supports with flexible end-to-end solutions to drive ongoing growth, increase operating efficiency and deliver greater value for clients.
  • With our new Growth Acceleration Platform for financial institutions-based wealth management programs, LaSalle St. is providing guidance that engages both institutional leaders and advisors in a holistic, customized service experience to help them more effectively pursue their goals for growth."
  • LaSalle St's Growth Acceleration Platform offers banks and credit unions and their financial advisors with:
    Ongoing support from LaSalle St. leadership, home-office staff and third-party experts in all aspects of practice management and business development.

Jacobs Selected for Design of Rock Island Connection (P2)

Retrieved on: 
Tuesday, September 29, 2020

DALLAS, Sept. 29, 2020 /PRNewswire/ -- Jacobs (NYSE:J) was selectedby Metra to provide engineering and design services for the Rock Island Connection (P2), as part of the Chicago Region Environmental and Transportation Efficiency ( CREATE ) Program's 75th Street Corridor Improvement Project ( 75th St. CIP ).

Key Points: 
  • DALLAS, Sept. 29, 2020 /PRNewswire/ -- Jacobs (NYSE:J) was selectedby Metra to provide engineering and design services for the Rock Island Connection (P2), as part of the Chicago Region Environmental and Transportation Efficiency ( CREATE ) Program's 75th Street Corridor Improvement Project ( 75th St. CIP ).
  • Combined for logistic and environmental reasons, the 75th St. CIP is the CREATE Program's largest project and addresses Chicago's top congestion point .
  • The SouthWest Service line Metra trains can then access LaSalle Street Station, allowing for additional passenger rail capacity at Union Station.
  • "The team that Jacobs has assembled to complete the design work represents an exciting opportunity to involve a number of local DBE's in this important project," said Metra CEO/Executive Director Jim Derwinski.

Reception for Artist Jesse Howard's "The Love & Hate of a Culture in Defiance" exhibition at the State Street Gallery at Robert Morris University

Retrieved on: 
Tuesday, October 1, 2019

Shelley LaMantia, director of the State Street Gallery, finds the exhibit to be visceral in its impact.

Key Points: 
  • Shelley LaMantia, director of the State Street Gallery, finds the exhibit to be visceral in its impact.
  • "The Love & Hate of a Culture in Defiance" continues at the State Street Gallery through October 31.
  • In all communications, please refer to the university by its full name, Robert Morris University Illinois.
  • *Higher Learning Commission of the North Central Association of Colleges and Schools, 30 N. LaSalle Street, Chicago, IL 60602, 312-263-0456.